轻型缺血性卒中与短暂性脑缺血发作后72小时内双联抗血小板治疗的获益持续时间与风险
本研究基于INSPIRES试验6,100例轻型缺血性卒中或高危TIA患者的二次分析,评估氯吡格雷-阿司匹林在症状发作72小时内启动的获益与风险持续时间。结果显示主要缺血事件减少主要发生在第一周(ARR 1.42%,95%CI 0.53%-2.32%),第二周(ARR 0.49%,95%CI 0.09%-0.90%)和第三周(ARR 0.29%,95%CI -0.05%至0.62%)仍有获益;中重度出血风险在前三周数值上较高但未达统计学显著。
要点
- 氯吡格雷-阿司匹林在症状发作72小时内启动,第一周主要缺血事件绝对风险降低1.42%(95%CI 0.53%-2.32%)。
- 第二周绝对风险降低0.49%(95%CI 0.09%-0.90%),第三周绝对风险降低0.29%(95%CI -0.05%至0.62%)。
- 前三周中重度出血绝对风险增加分别为0.05%、0.10%、0.18%,95%CI均跨0,未达统计学显著。
核心结论
- 在推测为动脉粥样硬化性病因的轻型缺血性卒中或高危TIA患者中,症状发作72小时内启动氯吡格雷-阿司匹林的净获益在第一周显著,随后两周以较小程度持续,超过低但持续存在的出血风险。
研究设计与样本
- INSPIRES试验是在中国222家医院开展的双因素2×2析因安慰剂对照随机试验,两种治疗无交互作用并分别评估。
- 本研究基于抗血小板治疗进行二次分析,纳入全部6,100例症状发作72小时内的轻型卒中或TIA患者,每组3,050例。
- 患者随机接受第1-21天氯吡格雷-阿司匹林后第22-90天氯吡格雷,或单独阿司匹林治疗90天。
- 平均年龄65岁,男性3,915例(64.2%)。
主要发现
- 与单独阿司匹林相比,氯吡格雷-阿司匹林减少主要缺血事件主要发生在第一周(绝对风险降低1.42%,95%CI 0.53%-2.32%)。
- 第二周绝对风险降低0.49%(95%CI 0.09%-0.90%),第三周绝对风险降低0.29%(95%CI -0.05%至0.62%)。
- 氯吡格雷-阿司匹林组前三周中重度出血绝对风险增加分别为0.05%(95%CI -0.10%至0.20%)、0.10%(95%CI -0.09%至0.29%)和0.18%(95%CI -0.03%至0.40%)。
关键数值与推荐
- 主要疗效结局为主要缺血事件,包括缺血性卒中与非出血性死亡的复合终点。
- 主要安全结局为中重度出血。
- 按分层周估计两种治疗的风险差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clopidogrel-aspirin initiated within 72 hours of symptom onset is effective in patients with mild ischemic stroke or transient ischemic attack (TIA) in the Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial. Uncertainties remain about the duration of the treatment effect. This study aimed to assess duration of benefit and risk of clopidogrel-aspirin in these patients. METHODS: The INSPIRES trial was a 2*2 factorial placebo-controlled randomized trial conducted in 222 hospitals in China. The 2 treatments did not interact and were evaluated separately. In this study, we performed secondary analyses based on antiplatelet treatment. All patients with mild stroke or TIA of presumed atherosclerotic cause within 72 hours of symptom onset enrolled in the trial were included. Patients were randomly assigned to receive clopidogrel-aspirin on days 1-21 followed by clopidogrel on days 22-90 or aspirin alone for 90 days. The primary efficacy outcome was major ischemic event which included the composite of ischemic stroke and nonhemorrhagic death. The primary safety outcome was moderate-to-severe bleeding. We estimated the risk difference between the 2 treatments for each stratified week. RESULTS: All 6,100 patients in the trial were included (3,050 in each group). The mean age was 65 years, and 3,915 patients (64.2%) were men. Compared with aspirin alone, the reduction of major ischemic events by clopidogrel-aspirin mainly occurred in the first week (absolute risk reduction [ARR] 1.42%, 95% CI 0.53%-2.32%) and remained in the second week (ARR 0.49%, 95% CI 0.09%-0.90%) and the third week (ARR 0.29%, 95% CI -0.05% to 0.62%). Numerical higher risk of moderate-to-severe bleedings in the clopidogrel-aspirin group was observed in the first 3 weeks (absolute risk increase 0.05% [95% CI -0.10% to 0.20%], 0.10% [95% CI -0.09% to 0.29%], and 0.18% [95% CI -0.03% to 0.40%] in the first, second, and third weeks, respectively). CONCLUSIONS: Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, the net benefit of clopidogrel-aspirin initiated within 72 hours of symptom onset was pronounced in the first week and continued to a lesser degree in the following 2 weeks, outweighing the low, but ongoing hemorrhagic risk. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03635749. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, the net benefit of clopidogrel-aspirin initiated within 72 hours of symptom onset was pronounced in the first week and continued to a lesser degree in the following 2 weeks, outweighing the low but ongoing hemorrhagic risk.
引用
- Guan L, Han S, Johnston SC, et al. Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack. Neurology. 2024. PMID: 39270151. doi:10.1212/WNL.0000000000209845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。